Wave Life Sciences Ltd. Ordinary Shares (WVE)

Price$5.73

Value ScoreC

Growth ScoreC

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-34.09%

Price vs S&P 500 (4W)-20.19%

VGM Score43.35

Market Capitalization$1.11B

All Metrics

Book Value / Share (Quarterly)$2.66

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)127.06%

Cash Flow / Share (Quarterly)$-0.96

Price vs S&P 500 (YTD)-74.45%

Net Profit Margin (TTM)-255.70%

EPS (TTM)$-1.05

10-Day Avg Trading Volume3.26M

EPS Excl Extra (TTM)$-1.05

Revenue Growth (5Y)16.30%

EPS (Annual)$-1.21

ROI (Annual)-38.84%

Net Profit Margin (5Y Avg)-1070.11%

Cash / Share (Quarterly)$2.83

Revenue Growth QoQ (YoY)316.85%

ROA (Last FY)-32.01%

Revenue Growth TTM (YoY)-31.58%

EBITD / Share (TTM)$-1.09

ROE (5Y Avg)-134.48%

Operating Margin (TTM)-274.21%

Cash Flow / Share (Annual)$-1.00

P/B Ratio2.17x

P/B Ratio (Quarterly)2.67x

Net Income / Employee (Annual)$-644,700

EV / Revenue (TTM)7.85x

ROA (TTM)-42.80%

EPS Incl Extra (Annual)$-1.21

Current Ratio (Annual)6.47x

Quick Ratio (Quarterly)11.00x

3-Month Avg Trading Volume4.24M

52-Week Price Return-15.11%

Revenue / Employee (TTM)$226,500

Tangible BV / Share (Quarterly)$-0.33

P/S Ratio (Annual)25.94x

Asset Turnover (Annual)0.07x

52-Week High$21.73

Operating Margin (5Y Avg)-1086.85%

EPS Excl Extra (Annual)$-1.21

CapEx CAGR (5Y)-11.73%

26-Week Price Return-26.16%

Quick Ratio (Annual)6.38x

13-Week Price Return-56.59%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)11.26x

Enterprise Value$563.65M

Revenue / Share Growth (5Y)-13.13%

Asset Turnover (TTM)0.17x

Book Value / Share Growth (5Y)6.05%

Revenue / Employee (Annual)$134,800

Pretax Margin (Annual)-478.33%

Cash / Share (Annual)$3.21

3-Month Return Std Dev112.75%

Net Income / Employee (TTM)$-579,100

ROE (Last FY)-38.84%

EPS Basic Excl Extra (Annual)$-1.21

Receivables Turnover (TTM)31.67x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.05

Receivables Turnover (Annual)31.67x

ROI (TTM)-55.74%

P/S Ratio (TTM)15.44x

Pretax Margin (5Y Avg)-1066.60%

Revenue / Share (Annual)$0.25

Tangible BV / Share (Annual)$-0.43

Price vs S&P 500 (52W)-39.48%

Year-to-Date Return-66.29%

5-Day Price Return-8.47%

EPS Normalized (Annual)$-1.21

ROA (5Y Avg)-50.01%

Net Profit Margin (Annual)-478.33%

Month-to-Date Return-12.92%

Cash Flow / Share (TTM)$-0.78

EBITD / Share (Annual)$-1.26

Operating Margin (Annual)-504.09%

ROI (5Y Avg)-134.48%

EPS Basic Excl Extra (TTM)$-1.05

P/B Ratio (Annual)5.91x

Pretax Margin (TTM)-255.70%

Book Value / Share (Annual)$2.80

Price vs S&P 500 (13W)-64.85%

Beta-1.28x

Revenue / Share (TTM)$0.36

ROE (TTM)-55.74%

52-Week Low$5.02

vGradeC

gGradeC

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.13est. -0.33

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.25

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
WVEWave Life Sciences Ltd. Ordinary Shares	C	C	D	$5.73
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

WAVE Life Sciences is a clinical-stage biotech company developing RNA medicines to treat rare and prevalent diseases using its proprietary PRISM platform. The platform combines multiple RNA-targeting modalities—RNA editing, antisense silencing, and RNA interference—with chemistry innovation and genetic insights to optimize drug design and delivery. WAVE's pipeline targets major market opportunities including obesity, Duchenne muscular dystrophy, Huntington's disease, and alpha-1 antitrypsin deficiency.